Ultragenyx Pharmaceutical Inc. received accelerated FDA approval for Genglycos, its first gene therapy, to treat the ultra-rare genetic disorder GSDIa. This approval is a significant milestone for the company, opening a new market and validating its gene therapy platform, leading to a substantial premarket stock price increase.
Ultragenyx Pharmaceutical Inc. (RARE) announced the accelerated FDA approval of Genglycos, its first gene therapy, for Glycogen Storage Disease Type Ia (GSDIa). This is a major positive catalyst for the company as it marks a significant entry into the gene therapy market and addresses an ultra-rare condition with a high unmet medical need. The approval, supported by Phase 3 data, is expected to generate substantial revenue, with analysts projecting $362 million in peak sales and a wholesale acquisition cost of $2.7 million per patient. Short-term, this led to an 11.28% premarket stock surge for RARE, and long-term, it validates Ultragenyx's R&D capabilities and pipeline, positioning it as a leader in rare disease treatments. The key opportunity for traders is the potential for continued growth as Genglycos rolls out commercially.